NCT00215904

D-serine Adjuvant Treatment for Parkinson's Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Herzog Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (\~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced dyskinesias. D-serine will be used as add-on therapy to on-going medications received by Parkinson's Disease patients. The rational for this study stems from observations made in pervious clinical trials with schizophrenia patients, in which it was demonstrated that D-serine adjuvant treatment resulted in:1)improvement of parkinsonian side effects induced by antipsychotic drugs and 2) improvement of depression and negative (i.e apathy, blunted effects, anhedonia) symptoms which are similar to symptoms encountered in Parkinson's Disease. The study will have a crossover design in accordance to which each patient will receive, in random order D-serine and placebo for a 6 weeks period each. Thus, any participant will have the opportunity to receive the experimental treatment.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	D-serine (~2g/day)	Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).

Timeline

• Start date: 2003-08-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2005-09-22
• Last updated: 2012-07-09

Locations

1 site across 1 country: Israel